Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
G1 Therapeutics Inc (GTHX)
NASDAQ:GTHX
G1 Therapeutics (GTHX) Stock Price & Analysis
1,864 Followers
GTHX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $6.14
Previous Close$2.47
Volume609.39K
Average Volume (3M)1.54M
Market Cap
$129.14M
Enterprise Value$110.99M
Total Cash (Recent Filing)$65.19M
Total Debt (Recent Filing)$47.04M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Jul 31, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding52,281,391
10 Day Avg. Volume614,937
30 Day Avg. Volume1,540,483
Standard Deviation0.29
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.66
Price to Sales (P/S)8.96
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.47
Enterprise Value/Ebitda-4.73
Forecast
1Y Price Target
$6.25Price Target Upside155.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
G1 Therapeutics News
PremiumCompany Announcements
G1 Therapeutics Reports Setback in Phase 3 Cancer Trial
Bulls Say, Bears Say
Bulls Say
Clinical ResultsNew positive Phase 2 results highlight the positive impact of Cosela in combination with Trodelvy on overall survival and tolerability in metastatic triple negative breast cancer patients.
Financial PerformanceThe company expects to have a sufficient cash runway to reach anticipated company profitability.
Strategic PartnershipsA global licensing agreement grants Deimos exclusive rights to develop, manufacture, and commercialize lerociclib for certain radioprotective uses in the U.S., Europe, Japan, and all other global markets, excluding the Asia-Pacific region.
Bears Say
Clinical TrialsTopline results from PRESERVE 2 trial did not reach statistical significance for overall survival.
Product PerformanceCosela sales were $14.1M in 1Q:24, slightly below our and Street estimates of ~$15M.
Sales PerformanceGrowth was negatively impacted by poor sales in the Southeast, fewer new patients added in December and January, which impacted continuing patients through the quarter, and three of its contracted customer networks performing below expectations.
---
Ownership Overview
22.70% Insiders
9.99% Mutual Funds
11.64% Other Institutional Investors
55.67% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GTHX FAQ
What was G1 Therapeutics Inc’s price range in the past 12 months?
G1 Therapeutics Inc lowest stock price was $1.08 and its highest was $6.14 in the past 12 months.
What is G1 Therapeutics Inc’s market cap?
Currently, no data Available
When is G1 Therapeutics Inc’s upcoming earnings report date?
G1 Therapeutics Inc’s upcoming earnings report date is Jul 31, 2024 which is in 28 days.
How were G1 Therapeutics Inc’s earnings last quarter?
G1 Therapeutics Inc released its earnings results on May 01, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.198 by -$0.002.
Is G1 Therapeutics Inc overvalued?
According to Wall Street analysts G1 Therapeutics Inc’s price is currently Undervalued.
Does G1 Therapeutics Inc pay dividends?
G1 Therapeutics Inc does not currently pay dividends.
What is G1 Therapeutics Inc’s EPS estimate?
G1 Therapeutics Inc’s EPS estimate is -$0.17.
How many shares outstanding does G1 Therapeutics Inc have?
G1 Therapeutics Inc has 52,281,390 shares outstanding.
What happened to G1 Therapeutics Inc’s price movement after its last earnings report?
G1 Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.198. Following the earnings report the stock price went up 9.549%.
Which hedge fund is a major shareholder of G1 Therapeutics Inc?
Among the largest hedge funds holding G1 Therapeutics Inc’s share is Graham Capital Management, L.P.. It holds G1 Therapeutics Inc’s shares valued at 83K.
---
G1 Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (155.10% Upside)
$6.25 (155.10% Upside)
Blogger Sentiment
Bullish
GTHX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 19.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $397.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.80%
12-Months-Change
Fundamentals
Return on Equity
-84.13%
Trailing 12-Months
Asset Growth
-37.00%
Trailing 12-Months
Company Description
G1 Therapeutics Inc
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
---
GTHX Earnings Call
Q1 2024
0:00 / 0:00
---
GTHX Stock 12 Month Forecast
Average Price Target
$6.25
▲(155.10% Upside)
Technical Analysis
Best Analysts Covering GTHX
1 Year
1 Year Success Rate
9/29 ratings generated profit
1 Year Average Return
-32.00%
reiterated a buy rating 8 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 31.03% of your transactions generating a profit, with an average return of -32.00% per trade.
---